000172546 001__ 172546
000172546 005__ 20240229133721.0
000172546 0247_ $$2doi$$a10.1093/nop/npab031
000172546 0247_ $$2pmid$$apmid:34594567
000172546 0247_ $$2pmc$$apmc:PMC8475219
000172546 0247_ $$2ISSN$$a2054-2577
000172546 0247_ $$2ISSN$$a2054-2585
000172546 0247_ $$2altmetric$$aaltmetric:106876708
000172546 037__ $$aDKFZ-2021-02094
000172546 041__ $$aEnglish
000172546 082__ $$a610
000172546 1001_ $$aHirsch, Steffen$$b0
000172546 245__ $$aCancer predisposition in pediatric neuro-oncology-practical approaches and ethical considerations.
000172546 260__ $$aOxford$$bOxford Univ. Press$$c2021
000172546 3367_ $$2DRIVER$$aarticle
000172546 3367_ $$2DataCite$$aOutput Types/Journal article
000172546 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1633697596_15819$$xReview Article
000172546 3367_ $$2BibTeX$$aARTICLE
000172546 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000172546 3367_ $$00$$2EndNote$$aJournal Article
000172546 500__ $$a#LA:B062#
000172546 520__ $$aA genetic predisposition to tumor development can be identified in up to 10% of pediatric patients with central nervous system (CNS) tumors. For some entities, the rate of an underlying predisposition is even considerably higher. In recent years, population-based approaches have helped to further delineate the role of cancer predisposition in pediatric oncology. Investigations for cancer predisposition syndrome (CPS) can be guided by clinical signs and family history leading to directed testing of specific genes. The increasingly adopted molecular analysis of tumor and often parallel blood samples with multi-gene panel, whole-exome, or whole-genome sequencing identifies additional patients with or without clinical signs. Diagnosis of a genetic predisposition may put an additional burden on affected families. However, information on a given cancer predisposition may be critical for the patient as potentially influences treatment decisions and may offer the patient and healthy carriers the chance to take part in intensified surveillance programs aiming at early tumor detection. In this review, we discuss some of the practical and ethical challenges resulting from the widespread use of new diagnostic techniques and the most important CPS that may manifest with brain tumors in childhood.
000172546 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000172546 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000172546 650_7 $$2Other$$acancer
000172546 650_7 $$2Other$$agenetics
000172546 650_7 $$2Other$$apediatrics
000172546 650_7 $$2Other$$apredisposition
000172546 7001_ $$aDikow, Nicola$$b1
000172546 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan M$$b2$$udkfz
000172546 7001_ $$0P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aPajtler, Kristian$$b3$$eLast author$$udkfz
000172546 773__ $$0PERI:(DE-600)2768945-1$$a10.1093/nop/npab031$$gVol. 8, no. 5, p. 526 - 538$$n5$$p526 - 538$$tNeuro-oncology practice$$v8$$x2054-2585$$y2021
000172546 909CO $$ooai:inrepo02.dkfz.de:172546$$pVDB
000172546 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000172546 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000172546 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000172546 9141_ $$y2021
000172546 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-09-06
000172546 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-09-06
000172546 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-09-06
000172546 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-09-06
000172546 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-09-06
000172546 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-09-06
000172546 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2020-09-06
000172546 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-09-06
000172546 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000172546 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000172546 980__ $$ajournal
000172546 980__ $$aVDB
000172546 980__ $$aI:(DE-He78)B062-20160331
000172546 980__ $$aI:(DE-He78)HD01-20160331
000172546 980__ $$aUNRESTRICTED